RxDoctor Payments Data

Mary Crutchfield

Psychiatric/Mental Health · Virginia Beach, VANPI 1366715112

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 456 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,932in general payments, 2019–2025

Across 456 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Tris Pharma Inc$931
  • Otsuka America Pharmaceutical, Inc.$915
  • Johnson & Johnson$780
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$557
  • Neurocrine Biosciences, Inc.$461
  • plus $3K from 19 others

What the payments were for

  • Food & beverage$7,88599%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,932 in reported general payments places this provider in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.

See all psychiatric/mental health providers in Virginia

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lurasidone Hcl14$2,612
Venlafaxine Hcl ErVenlafaxine Hcl20$1,704
Olanzapine21$527
Methylphenidate Hcl21$501
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine16$483
Clonazepam29$449
Escitalopram Oxalate21$351
Gabapentin21$213
Trazodone Hcl18$209
Fluoxetine Hcl23$171
Diazepam14$151
Lamotrigine12$128
Sertraline Hcl23$31
Buspirone Hcl23$22

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$60$52721 claims
Almatica Pharma LLCSertraline Hcl$20$3123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.

Other psychiatric/mental health in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →